Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Zolmitriptan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D known ✓ | P28221 | 11/20 | 0.98 |
| ▸ | HTR1B known ✓ | P28222 | 11/20 | 0.98 |
| ▸ | HTR1A | P08908 | 10/20 | 0.98 |
| ▸ | HTR2A | P28223 | 5/20 | 0.98 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.98 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.98 |
| ▸ | HTR1F | P30939 | 2/20 | 0.62 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.54 |
| ▸ | HTR5A | P47898 | 4/20 | 0.53 |
| ▸ | HTR2C | P28335 | 3/20 | 0.53 |
| ▸ | HTR2B | P41595 | 2/20 | 0.53 |
| ▸ | HTR1E | P28566 | 1/20 | 0.53 |
| ▸ | HTR7 | P34969 | 1/20 | 0.53 |
| ▸ | HTR3A | P46098 | 1/20 | 0.53 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Zolmitriptan SCHEMBL14861150 | 0.99 | HTR1D (1.00) | HTR1DHTR1BHTR1AHTR2AKMT2A | |
| Zolmitriptan SCHEMBL33336 | 0.99 | HTR1D (1.00) | HTR1DHTR1BHTR1AHTR2AKMT2A | |
| Zolmitriptan SCHEMBL4427888 | 0.99 | HTR1D (1.00) | HTR1DHTR1BHTR1AHTR2AKMT2A | |
| Zolmitriptan SCHEMBL40595 | 0.99 | HTR1D (1.00) | HTR1DHTR1BHTR1AHTR2AKMT2A | |
| Zolmitriptan SCHEMBL29835946 | 0.99 | HTR1D (1.00) | HTR1DHTR1BHTR1AHTR2AKMT2A | |
| Zolmitriptan SCHEMBL1246512 | 0.99 | HTR1D (1.00) | HTR1DHTR1BHTR1AHTR2AKMT2A | |
| Zolmitriptan SCHEMBL29356689 | 0.99 | HTR1D (1.00) | HTR1DHTR1BHTR1AHTR2AKMT2A | |
| Zolmitriptan SCHEMBL2377949 | 0.98 | HTR1D (0.98) | HTR1DHTR1BHTR1AHTR2AKMT2A | |
| Zolmitriptan SCHEMBL2540996 | 0.95 | HTR1D (0.92) | HTR1DHTR1BHTR1AHTR2AKMT2A | |
| Zolmitriptan SCHEMBL2376692 | 0.94 | HTR1D (0.90) | HTR1DHTR1BHTR1AHTR2AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2118095-B1 | A METHOD FOR THE PREPARATION OF ZOLMITRIPTAN | ZENTIVA KS (CZ) | 2010-11-03 | — | — | EP | claimed |
| US-20100145064-A1 | METHOD FOR THE PREPARATION OF ZOLMITRIPTAN | ZENTIVA K.S. (CZ) | 2010-06-10 | — | — | US | claimed |
| EP-2118095-A1 | A METHOD FOR THE PREPARATION OF ZOLMITRIPTAN | Zentiva, A.S. (CZ) | 2009-11-18 | — | — | EP | claimed |
| WO-2008104135-A1 | A METHOD FOR THE PREPARATION OF ZOLMITRIPTAN | ZENTIVA, A.S. (CZ) | 2008-09-04 | — | — | WO | claimed |
| CN-115038451-A | Multimodal compositions and methods of treatment | 阿奎斯蒂弗医疗股份有限公司 | 2022-09-09 | — | — | CN | disclosed |
| CN-115003279-A | Prodrug compositions and methods of treatment | 阿奎斯蒂弗医疗股份有限公司 | 2022-09-02 | — | — | CN | disclosed |
| CN-112585690-A | System and method for producing individualized individual unit doses containing a pharmaceutically active substance | 阿奎斯蒂弗医疗股份有限公司 | 2021-03-30 | — | — | CN | disclosed |
| CN-102264395-A | Liquid pharmaceutical compositions comprising a triptan compound and xylitol | — | 2011-11-30 | — | — | CN | disclosed |
| US-20110257228-A1 | LIQUID PHARMACEUTICAL COMPOSITIONS COMPRISING A TRIPTAN COMPOUND AND XYLITOL | ALMIRALL, S.A. (ES) | 2011-10-20 | — | — | US | disclosed |
| EP-2367573-A1 | LIQUID PHARMACEUTICAL COMPOSITIONS COMPRISING A TRIPTAN COMPOUND AND XYLITOL | Almirall S.A. (ES) | 2011-09-28 | — | — | EP | disclosed |
| EP-2118095-B1 | A METHOD FOR THE PREPARATION OF ZOLMITRIPTAN | ZENTIVA KS (CZ) | 2010-11-03 | — | — | EP | disclosed |
| EP-2118095-B1 | A METHOD FOR THE PREPARATION OF ZOLMITRIPTAN | ZENTIVA KS (CZ) | 2010-11-03 | — | — | EP | disclosed |
| EP-2198889-A1 | Liquid pharmaceutical compositions comprising a triptan compound and Xylitol | Almirall, S.A. (ES) | 2010-06-23 | — | — | EP | disclosed |
| US-20100145064-A1 | METHOD FOR THE PREPARATION OF ZOLMITRIPTAN | ZENTIVA K.S. (CZ) | 2010-06-10 | — | — | US | disclosed |
| US-20100145064-A1 | METHOD FOR THE PREPARATION OF ZOLMITRIPTAN | ZENTIVA K.S. (CZ) | 2010-06-10 | — | — | US | disclosed |
| EP-2118095-A1 | A METHOD FOR THE PREPARATION OF ZOLMITRIPTAN | Zentiva, A.S. (CZ) | 2009-11-18 | — | — | EP | disclosed |
| EP-2118095-A1 | A METHOD FOR THE PREPARATION OF ZOLMITRIPTAN | Zentiva, A.S. (CZ) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008140453-A1 | IONTOPHORETIC DEVICES FOR DRUG DELIVERY | VYTERIS, INC. (US) | 2008-11-20 | — | — | WO | disclosed |
| WO-2008104135-A1 | A METHOD FOR THE PREPARATION OF ZOLMITRIPTAN | ZENTIVA, A.S. (CZ) | 2008-09-04 | — | — | WO | disclosed |
| WO-2008104135-A1 | A METHOD FOR THE PREPARATION OF ZOLMITRIPTAN | ZENTIVA, A.S. (CZ) | 2008-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100145064-A1 | METHOD FOR THE PREPARATION OF ZOLMITRIPTAN | LPXN, TREH, HTR3A | HTR1D 148/4885HTR1B 191/4885HTR1A 76/4885 |
| US-20110257228-A1 | LIQUID PHARMACEUTICAL COMPOSITIONS COMPRISING A TRIPTAN COMPOUND AND XYLITOL | SLC5A1, TREH, SLC5A2 | HTR1D 430/4885HTR1B 794/4885HTR1A 822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.